Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Atezolizumab + Imatinib

Stage Phase 2

Sponsor Centre Leon Berard

Class anti-PD-L1 (with imatinib)

Target PD-L1 (TEC-0014)

Target KIT (TEC-0117)

Sources

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/40368739/

PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.

Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05152472

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

ATEZOGIST

Registry NCT05152472

Phase Phase 2

Status Active, not recruiting

Enrollment 58

Start 2022-01-14

Primary completion 2027-10

Study completion 2027-10

Catalyst Primary completion. 10.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.